A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2029-01-17
Target enrollment:
Participant gender:
Summary
TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve
MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end
of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at
the end of AVR induction will be randomised to continued acalabrutinib or observation.
Participants who progress during observation may receive retreatment with acalabrutinib